BEDFORD, TX, Feb. 28, 2013 /PRNewswire/ - Invaron Pharmaceuticals Inc. clinical
partner, the Center for Assisted Reproduction (CARE), led by Kevin
Doody M.D., today initiated an investigator led, IRB approved Phase III
study using INVOcellTM in patients with tubal blockage or unexplained infertility that require
in vitro fertilization.
INVOcellTM is an innovative medical device used in infertility treatment which
enables conception and early embryo development to occur within a
woman's own body rather than in a laboratory. "The primary focus of
the study will be to first evaluate the comfort and retention of the
system over 5 days to ensure that INVOcellTM performs similarly to existing 3 day retention data," remarked Dr.
Kevin Doody. "We will then examine how INVOcellTM compares to conventional IVF in an open label extension, examining the
quality day 5 embryos, known as blastocysts, and ultimately pregnancy
and live birth rates".
"We are excited at the prospect of partnering with CARE and Dr. Kevin
Doody as part of our Phase III/IV clinical program in the United States
and Canada," said Jason Broome, President and COO of Invaron
Pharmaceuticals. "IVF is increasingly utilizing day 5 embryo culture
and this data will ultimately serve to broaden the use of INVOcellTM".
Patients interested in learning more are encouraged to contact the
Center for Assisted Reproduction in Bedford Texas directly.
About Invaron Pharmaceuticals
Invaron is a Canadian based pharmaceutical company focusing exclusively
on the acquisition of niche drugs and medical devices registered in
other countries but not in Canada. By facilitating local registration,
bridging clinical gaps, and launching innovative marketing strategies,
Invaron will effectively meet the under serviced needs of Canadian
patients in a wide variety of therapeutic areas. Invaron encourages
patients, physicians, potential pharmaceutical partners and other
stakeholders to visit www.invaron.ca to learn more.
About the Centre for Assisted Reproduction (CARE)
CARE is an independent facility providing comprehensive medical care for
the treatment of infertile patients. Established in 1989, CARE has been
providing state-of-the-art fertility treatment to residents of Dallas,
Fort Worth, and cities throughout the state of Texas. CARE strives to
make it easy for patients to receive cutting-edge treatment and
maintains longstanding relationships with all major managed care
organizations. CARE offers a comprehensive suite of services including
IVF and egg donation. CARE centers are conveniently located in
Bedford, Fort Worth and Frisco, Texas. Visit www.embryo.net to learn more.
INVOcellTM a registered trademark of INVO Bioscience, Inc. used under license by
Invaron Pharmaceuticals Inc.
SOURCE Invaron Pharmaceuticals Inc.